glp-1 drugs cancer may reduce the risk of progressing, study suggests Research Reveals Potential Risks of
Description
WH, RS, RC, CL, RG, WT, JZ and QZ drafted and revised the manuscript
Survodutide# Survodutide similarly activates GLP-1 and glucagon receptors, leveraging Zealand Pharma's peptide technology platform
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, et al
Additionally, DMS treatment led to a reduction in monocyte and macrophage populations while increasing the absolute number of ILC3s, thereby enhancing IL-22 production
